Kyverna Therapeutics

Kyverna Therapeutics A patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients living with autoimmune disease.

We place patients at the core of our mission. As a clinical-stage biopharmaceutical company, we are dedicated to advancing cell therapies for individuals struggling with autoimmune diseases. On our Kyverna page, you can connect with us and gain insights into our company. We'll share company updates, educational materials, and stories from our patients and healthcare professionals. Our aim

is to actively engage with our community, offering valuable information and encouraging respectful discussions about the diseases we strive to address. The content of this page is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Kyverna’s Sunetra Biswas had the pleasure of recently attending Myasthenia Gravis Foundation of America, Inc. (MGFA)’s S...
06/05/2026

Kyverna’s Sunetra Biswas had the pleasure of recently attending Myasthenia Gravis Foundation of America, Inc. (MGFA)’s San Diego Health Fair, sharing information about our Phase 3 CAR T-cell therapy clinical trial in generalized myasthenia gravis (gMG), KYSA-6.

As we kick off MG Awareness Month, we’re grateful to the MGFA for the opportunity to connect with people living with MG and their caregivers, and to support this incredible community.

Learn more by visiting: https://www.myastheniagravistrials.com/

05/21/2026

This , we’re honored to spotlight this video of Tara Zier, CEO of The Stiff Person Syndrome Research Foundation, and her perspective on the mental health impact of .

SPS is a rare, progressive disease and the need for an approved treatment option is urgent. Like many rare diseases, SPS affects more than physical health; it can also impact emotional well-being, relationships, and daily life.

At Kyverna, we’re proud to help amplify voices that foster connection, awareness, and hope. Our commitment to advancing innovative CAR T therapies is driven by the urgent needs of people living with SPS and their families.

Explore resources from the SPSRF here: https://www.stiffperson.org/sps-resources

We’re very pleased to share positive primary analysis results from our registrational trial in : https://ir.kyvernatx.c...
04/21/2026

We’re very pleased to share positive primary analysis results from our registrational trial in : https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-presents-registrational-trial-primary-analysis-miv-cel

The findings, featured as a late-breaking oral presentation at the American Academy of Neurology (AAN)’s , underscore the potential for our investigational CAR T-cell therapy, miv-cel, to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for this rare, progressive disease.

We’re pleased to share positive longer-term follow-up Phase 2 data for our investigational CAR T-cell therapy, miv-cel, ...
04/20/2026

We’re pleased to share positive longer-term follow-up Phase 2 data for our investigational CAR T-cell therapy, miv-cel, in generalized : https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-presents-longer-term-phase-2-data-miv-cel-generalized

The data, featured as an oral presentation at the American Academy of Neurology’s , reinforce miv-cel’s potential to set a new clinical standard in gMG. For people navigating , progress matters. We’re grateful to the trial participants and clinical investigators who make it possible.

Congratulations to the Myasthenia Gravis Foundation of America, Inc. on another successful National Patient Conference! ...
04/15/2026

Congratulations to the Myasthenia Gravis Foundation of America, Inc. on another successful National Patient Conference! We are grateful for the opportunity to engage with the community of caregivers and patients like Kathy Timothy who shared why this event is so valuable.

To learn more about our KYSA-6 CAR T clinical trial in gMG, visit: myastheniagravistrials.com

Happy Holidays from all of us at Kyverna!
12/23/2024

Happy Holidays from all of us at Kyverna!

12/09/2024

Listen how Kyverna answers the top questions we received from patients, caregivers, and loved ones regarding .

Find out more from Dominic, our President, Research & Development, as he shares more about our future plans for other autoimmune diseases.

We believe in educated patients. If CAR T-cell therapy is something you are interested in, please consult treatment options with your doctor or further inquire by emailing [email protected].

12/06/2024

Listen how Kyverna answers the top questions we received from patients, caregivers, and loved ones regarding .

Find out more from James, our Chief Medical Officer, as he discusses our ongoing clinical trials.

We believe in educated patients. If CAR T-cell therapy is something you are interested in, please consult treatment options with your doctor or further inquire by emailing [email protected].

12/02/2024

Listen how Kyverna answers the top questions we received from patients, caregivers, and loved ones regarding .

Find out more from Arie, our Vice President, Market Access, as he discusses the current access to CAR T-cell therapy.

We believe in educated patients. If CAR T-cell therapy is something you are interested in, please consult treatment options with your doctor or further inquire by emailing [email protected].

11/29/2024

Listen how Kyverna answers the top questions we received from patients, caregivers, and loved ones regarding .

Find out more from Arie, our Vice President, Market Access, as he shares more information about the cost of CAR T-cell therapy.

We believe in educated patients. If CAR T-cell therapy is something you are interested in, please consult treatment options with your doctor or further inquire by emailing [email protected].

Address

5980 Horton Street, Suite 200
Emeryville, CA
94608

Website

Alerts

Be the first to know and let us send you an email when Kyverna Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Kyverna Therapeutics:

Shortcuts

Share

Category